Dong-A ST wants competing product, Forsteo, to receive insurance benefit for its products, Teribone

Dong-A ST has paid attention to the availability of the health insurance benefit of ‘Forsteo,’ an osteoporosis treatment which has not received the insurance benefit already for 10 years. 

This is because ‘Teribone Inj 56.5mcg’ which was domestically approved on the November of the last year is also an osteogenesis-promotion enhancer just like Forsteo.

The Teribone’s chance to receive the ben...